Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Eliquis | Apixaban | Thromboembolic events prevention, (atrial fibrillation) | List with clinical criteria and/or conditions | Complete | ||
Eliquis | Apixaban | Venous thromboembolic events, treatment and prevention of recurrence | List with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | ||
Otezla | Apremilast | Plaque psoriasis | Do not list | Complete | ||
Otezla | Apremilast | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Emend | Aprepitant | Nausea and Vomiting, Chemotherapy induced | List with clinical criteria and/or conditions | Complete | ||
Abilify | Aripiprazole | Schizophrenia | Do not list | Complete |